King’s Bigger Bid Still Too Low, Alpharma Board Says
Alpharma urges shareholders to reject King’s $37 per-share bid, as the firm pursues a sale at a higher price.
Alpharma urges shareholders to reject King’s $37 per-share bid, as the firm pursues a sale at a higher price.